Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AXGN vs AHCO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AXGN Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 4–5 Matrix Metrics)

AXGN Overall Winner 6-Pillar Tally: AXGN 5 – 1 AHCO Matrix Metrics: AXGN 4 – 5 AHCO

As of Nov 20, 2026, Axogen, Inc. (AXGN) is the stronger overall head-to-head candidate over AdaptHealth Corp. (AHCO) in the Tradestie Institutional Equity Comparison Engine, winning 4–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AXGN carries a Unified Composite Score of 35.7/100 (SELL) at $55.75 (79.0x Forward P/E, -5.2% operating margin), whereas AHCO carries 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin).

  • Composite vs. Pillar Nuance: While AHCO currently prints a higher short-term Unified Composite Score (45.2/100 HOLD vs. AXGN 35.7/100 SELL), AXGN captures the overall institutional head-to-head verdict (4–5 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-5.2% vs. 3.8% operating margin) and revenue trajectory (+26.2% vs. +10.9% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AXGN vs AHCO
AXGN NASDAQ Head-to-Head Winner
Axogen, Inc. Common Stock
Electromedical & Electrotherapeutic Apparatus
$55.75
-1.06% 1D
Market Cap $3.4B
TTM Revenue $267M
Forward P/E 79.0x
Beta / 30D Vol 1.22β · 121% Vol
Unified Composite Score
35.7 / 100 SELL
Tech 50.0 Fund 30.0 Flow 64.0 Mom 31.6
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.5% over 20 days), RSI 66
RSI-14: 66.4 · SMA20: $51.22 · SMA50: $44.34
AHCO NASDAQ
AdaptHealth Corp. Common Stock
Services-Home Health Care Services
$7.20
-0.69% 1D
Market Cap $989.8M
TTM Revenue $3.44B
Forward P/E 7.8x
Beta / 30D Vol 0.17β · 67% Vol
Unified Composite Score
45.2 / 100 HOLD
Tech 29.0 Fund 46.0 Flow 54.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.8% over 20 days), RSI 57
RSI-14: 57.1 · SMA20: $6.96 · SMA50: $6.32

6-Pillar Scorecard Institutional Category Breakdown (AXGN 5 – 1 AHCO)

Columns: Metric · AXGN · AHCO
1. Valuation Multiples AHCO
Forward P/E 79.0x 7.8x
Trailing P/E 125.0x 7.8x
PEG Ratio N/M N/M
EV / Revenue 11.5x 0.9x
2. Growth & Scale AXGN
Revenue Growth (YoY) +26.2% +10.9%
Earnings Growth (YoY) +300.0% +6.7%
TTM Revenue (USD) $267M $3.44B
Market Cap $3.4B $989.8M
3. Profitability & Quality AXGN
Gross Margin 74.2% 18.2%
Operating Margin -5.2% 3.8%
Net Profit Margin -12.0% -11.8%
Return on Equity (ROE) -10.3% -28.4%
4. Balance Sheet & Cash Flow AXGN
Cash Generation (TTM) $20M $82M
Cash Flow Margin 7.5% 2.4%
Net Cash / Leverage $309M Net Cash $1.97B Net Debt (1.67x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AXGN
Options Structure Phase SURGE SURGE
Current IV / %ile 72.6% (17th %ile) 66.9% (12th %ile)
Put/Call OI Skew 0.10x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat AXGN
OpEx & R&D Intensity 79.4% of Rev ($212M) 14.4% of Rev ($495M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AXGN (4) vs AHCO (5)
Institutional Metric AXGN AHCO Criterion Row Edge
Market Capitalization
Scale
$3.4B $989.8M Larger Scale AXGN
Trailing P/E Ratio
Valuation
125.0x 7.8x Lower Multiple AHCO
Forward P/E Ratio
Valuation
79.0x 7.8x Lower Multiple AHCO
Revenue Growth (YoY)
Growth
+26.2% +10.9% Higher Growth AXGN
Operating Margin (TTM)
Profitability
-5.2% 3.8% Higher Margin AHCO
Net Profit Margin
Profitability
-12.0% -11.8% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-10.3% -28.4% Higher ROE AXGN
52-Week Range Position
Momentum
89% ($24–$60) 24% ($5–$13) Stronger Trend AXGN
Beta / 30D Volatility
Risk Regime
1.22β · 121% Vol 0.17β · 67% Vol Lower Realized Risk AHCO
Unified Institutional Score
Composite Signal
35.7 / 100 (SELL) 45.2 / 100 (HOLD) Higher Composite AHCO
Trailing 12M Revenue (USD)
Operating Scale
$267M $3.44B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
74.2% 18.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 11.5x EV/Rev N/M PEG · 0.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$20M ($309M Net Cash) $82M ($1.97B Net Debt (1.67x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AXGN +35.3 pp
AXGN: +51.99% · AHCO: +16.69%
3M Horizon AHCO +14.65 pp
AXGN: +13.24% · AHCO: +27.89%
6M Horizon AXGN +67.41 pp
AXGN: +36.31% · AHCO: -31.1%
1Y Horizon AXGN +141.58 pp
AXGN: +120.7% · AHCO: -20.88%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period AXGN Revenue AHCO Revenue AXGN Op. Margin AHCO Op. Margin Margin Leader
FY2018 $80M $350M -24.4% 9.0% AHCO
FY2019 $110M $530M -29.4% 5.5% AHCO
FY2020 $110M $1.06B -20.6% 6.8% AHCO
FY2021 $130M $2.45B -20.0% 9.2% AHCO
FY2022 $140M $2.97B -21.4% 6.4% AHCO
FY2023 $160M $3.20B -13.5% -18.7% AXGN
FY2024 $190M $3.26B -1.8% 8.1% AHCO
FY2025 $230M $3.24B -3.5% 2.8% AHCO

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AXGN SURGE
7d in phase · OBV NEUTRAL
Current IV 72.6%
IV Percentile 17th %ile
Put/Call OI Skew 0.10x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact AXGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AHCO SURGE
6d in phase · OBV NEUTRAL
Current IV 66.9%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact AHCO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AXGN Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $3.4B market capitalization and -5.2% operating margin.
OpEx & R&D Reinvestment 79.4% of Rev ($212M)
90D Engineering Disclosures 0 Published
AHCO Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $989.8M market capitalization and 3.8% operating margin.
OpEx & R&D Reinvestment 14.4% of Rev ($495M)
90D Engineering Disclosures 0 Published

Investor FAQ AXGN vs AHCO Key Questions & Quantitative Answers

As of Nov 20, 2026, Axogen, Inc. (AXGN) is the stronger overall head-to-head candidate over AdaptHealth Corp. (AHCO) in the Tradestie Institutional Equity Comparison Engine, winning 4–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AXGN carries a Unified Composite Score of 35.7/100 (SELL) at $55.75 (79.0x Forward P/E, -5.2% operating margin), whereas AHCO carries 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin). Composite vs. Pillar Nuance: While AHCO currently prints a higher short-term Unified Composite Score (45.2/100 HOLD vs. AXGN 35.7/100 SELL), AXGN captures the overall institutional head-to-head verdict (4–5 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-5.2% vs. 3.8% operating margin) and revenue trajectory (+26.2% vs. +10.9% YoY).

AXGN leads the Growth & Scale pillar: AXGN posts +26.2% YoY revenue growth and +300.0% YoY earnings growth on $267M TTM revenue (74.2% gross margin, -5.2% operating margin), compared with AHCO at +10.9% YoY revenue growth and +6.7% YoY earnings growth on $3.44B TTM revenue (18.2% gross margin, 3.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), AXGN cumulative revenue shifted +187.5% while AHCO shifted +825.7%. In operating R&D and SG&A reinvestment, AXGN deploys 79.4% of Rev ($212M) (0 90-day corporate R&D disclosures) versus 14.4% of Rev ($495M) (0 disclosures) for AHCO.

AHCO screens cheaper on headline valuation multiples. AXGN trades at 79.0x Forward P/E, 125.0x Trailing P/E, N/M PEG, and 11.5x EV/Revenue (7.5% FCF margin), whereas AHCO trades at 7.8x Forward P/E, 7.8x Trailing P/E, N/M PEG, and 0.9x EV/Revenue (2.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AXGN (-10.3% ROE) versus AHCO (-28.4% ROE) capital efficiency.

In options market volatility and institutional positioning, AXGN carries 72.6% implied volatility (17th %ile, Compressed (<25th %ile)), a 0.10x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.22β · 121% Vol realized risk). By comparison, AHCO carries 66.9% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.17β · 67% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.